A. Cseh

916 citations

39 papers · 604 indexed · h-index 12

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 33
- HER2/EGFR in Cancer Research 12
- Colorectal Cancer Treatments and Studies 11
- Lung Cancer Research Studies 9
- Peptidase Inhibition and Analysis 9
Pulmonary and Respiratory Medicine 37
- Lung Cancer Treatments and Mutations 37

Co-authors: Flavio Solca (11 shared papers)Maximilian J. Hochmair (6 shared papers)Petr Kavan (3 shared papers)David A. Reardon (3 shared papers)Helmut Prosch (2 shared papers)Otto C. Burghuber (2 shared papers)Sophia Schwab (2 shared papers)Martin Filipits (2 shared papers)
Journals: Annals of Oncology (11 papers)Journal of Thoracic Oncology (9 papers)Future Oncology (2 papers)OncoTargets and Therapy (2 papers)Frontiers in Oncology (2 papers)
Partner nations: Austria United States Germany

In The Last Decade

A. Cseh

36 papers receiving 596 citations

Peers

Countries citing papers authored by A. Cseh

Since Specialization

Citations

This map shows the geographic impact of A. Cseh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Cseh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Cseh more than expected).

Fields of papers citing papers by A. Cseh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Cseh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Cseh. The network helps show where A. Cseh may publish in the future.

Co-authors

The 25 scholars most cited alongside A. Cseh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. Cseh Line = papers co-authored together A. Cseh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma Neuro-Oncology ·David A. Reardon, Burt Nabors, Warren Mason, James Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, A. Cseh, Yan Fu, Cong Jiang, Sven Wind, David D. Eisenstat	2014	134
2	NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents Annals of Oncology ·Janessa Laskin, Stephen V. Liu, Khaled Tolba, Christoph Heining, Richard F. Schlenk, Parneet Cheema, J. Cadranel, Martin Jones, Alexander Drilon, A. Cseh, Steve Gyorffy, Flavio Solca, M. Duruisseaux	2020	93
3	Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib Targeted Oncology ·Maximilian J. Hochmair, Anna Buder, Sophia Schwab, Otto C. Burghuber, Helmut Prosch, Wolfgang Hilbe, A. Cseh, Richard R. Fritz, Martin Filipits	2018	89
4	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Journal of Thoracic Oncology ·Solange Peters, Alessandra Curioni‐Fontecedro, Hovav Nechushtan, Jin‐Yuan Shih, Wei‐Yu Liao, Oliver Gautschi, Vito Spataro, Mojca Unk, James Chih‐Hsin Yang, Robert M. Lorence, Philippe Carrière, A. Cseh, Gee‐Chen Chang	2018	66
5	Therapeutic Potential of Afatinib inNRG1Fusion-Driven Solid Tumors: A Case Series The Oncologist ·J. Cadranel, Stephen V. Liu, M. Duruisseaux, Eva Brandén, Yasushi Goto, Benjamin A. Weinberg, Christoph Heining, Richard F. Schlenk, Parneet Cheema, Martin Jones, Alexander Drilon, Domenico Trombetta, Lucia Anna Muscarella, Khaled Tolba, V. Gounant, A. Cseh, Flavio Solca, Janessa Laskin, Daniel J. Renouf	2020	41
6	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer Journal of Thoracic Oncology ·Federico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, Paolo Bidoli, Adolfo Favaretto, Antonio Marchetti, Marialuisa Valente, A. Cseh, L. Clementi, Dan Massey, Armando Santoro	2014	22
7	Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study Lung Cancer ·Filippo de Marinis, К. К. Лактионов, Artem Poltoratskiy, I. Egorova, Maximilian J. Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi, Gyula Ostoros, Simona Rizzato, Guzel Mukhametshina, Michael A. Schumacher, Silvia Novello, Rafał Dziadziuszko, Wenbo Tang, L. Clementi, A. Cseh, Dariusz M. Kowalski	2020	20
8	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report Oncotarget ·Jad Alshami, Marie‐Christine Guiot, Scott Owen, Petr Kavan, Neil Gibson, Flavio Solca, A. Cseh, David A. Reardon, Thierry Muanza	2015	16
9	Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation Frontiers in Oncology ·Sabine Zöchbauer‐Müller, Bettina Kaserer, Helmut Prosch, A. Cseh, Flavio Solca, Markus Bauer, Leonhard Müllauer	2021	12
10	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies Frontiers in Oncology ·Antonio Passaro, Filippo de Marinis, Hai‐Yan Tu, К. К. Лактионов, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz M. Kowalski, Cheng‐Ta Yang, B. Srinivasa, L. Clementi, Tejaswini Jalikop, Dennis Huang, A. Cseh, Keunchil Park, Yi‐Long Wu	2021	12
11	Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial Journal of Neuro-Oncology ·Frank Saran, Liam Welsh, Allan James, Catherine McBain, Rao Gattamaneni, Sarah Jefferies, Fiona Harris, Karine Pemberton, Jennifer Schaible, Shaun Bender, A. Cseh, Michael Brada	2021	12
12	Global Named Patient Use Program of Afatinib in Advanced Non-Small-Cell Lung Carcinoma Patients Who Progressed Following Prior Therapies Future Oncology ·Federico Cappuzzo, Ross A. Soo, Maximilian J. Hochmair, Martin Schüler, Kwok Chi Lam, G. Stehle, A. Cseh, Robert M. Lorence, Stephan Linden, Nicole D Forman, Wolfgang Hilbe, Abdul Rahman Jazieh, Chun‐Ming Tsai	2018	12
13	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial EClinicalMedicine ·Glenwood Goss, Manuel Cobo, Shun Lü, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young Joo Min, Andrea Ardizzoni, Shaun Bender, A. Cseh, Enriqueta Felip	2021	9
14	P2.03-025 Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib Journal of Thoracic Oncology ·Maximilian J. Hochmair, Sophia Schwab, Otto C. Burghuber, R. Koger, Ulrike Setinek, A. Cseh, Richard R. Fritz, Anna Buder, Martin Filipits	2017	8
15	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung OncoTargets and Therapy ·Shun Lü, Wěi Li, Caicun Zhou, Chengping Hu, Shukui Qin, Gang Cheng, Jifeng Feng, Jie Wang, A. Cseh, Barbara Peil, Neil Gibson, E. Ehrnrooth, Li Zhang	2018	7
16	Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors. Journal of Global Oncology ·Janessa Laskin, J. Cadranel, Daniel J. Renouf, Benjamin A. Weinberg, Yasushi Goto, M. Duruisseaux, Khaled Tolba, Eva Brandén, Robert C. Doebele, Christoph Heining, Richard F. Schlenk, Parneet Cheema, Martin Jones, Domenico Trombetta, Lucia Anna Muscarella, A. Cseh, Flavio Solca, Stephen V. Liu	2019	5
17	Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA Clinical Lung Cancer ·Edward S. Kim, Jonathan Kish, A. Cseh, Barbara Moehring, Wenbo Tang, E. Terlizzi, Janakiraman Subramanian	2021	4
18	Efficacy and Safety Results of the Afatinib Expanded Access Program Oncology and Therapy ·Edward S. Kim, Balázs Halmos, Ingrid F. Kohut, Taral Patel, Regan Rostorfer, Alexander I. Spira, A. Cseh, John McKay, G. Wallenstein, Kathryn F. Mileham	2017	4
19	Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option Annals of Oncology ·Stephen V. Liu, M. Duruisseaux, Khaled Tolba, Eva Brandén, Yasushi Goto, Benjamin A. Weinberg, Daniel J. Renouf, Robert C. Doebele, Christoph Heining, Richard F. Schlenk, Parneet Cheema, J. Cadranel, Martin Jones, Alexander Drilon, Domenico Trombetta, Lucia Anna Muscarella, A. Cseh, Flavio Solca, Janessa Laskin	2019	4
20	NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option Annals of Oncology ·Benjamin A. Weinberg, Daniel J. Renouf, Howard J. Lim, Christoph Heining, Richard F. Schlenk, Martin Jones, S. Liu, A. Cseh, Flavio Solca, Janessa Laskin	2019	3

About A. Cseh

A. Cseh is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Neurology and Gastroenterology, having authored 39 papers that have together received 604 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (37 papers), HER2/EGFR in Cancer Research (12 papers), Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Research Studies (9 papers), Peptidase Inhibition and Analysis (9 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer therapeutics and mechanisms (4 papers) and Glioma Diagnosis and Treatment (4 papers). The work is most often cited by research in Oncology (393 citations), Pulmonary and Respiratory Medicine (401 citations), Genetics (128 citations), Cancer Research (163 citations) and Pathology and Forensic Medicine (50 citations). A. Cseh has collaborated with scholars based in Austria, United States and Germany. Frequent co-authors include Flavio Solca, Maximilian J. Hochmair, Petr Kavan, David A. Reardon, Helmut Prosch, Otto C. Burghuber, Sophia Schwab, Martin Filipits, Wolfgang Hilbe and Anna Buder. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Future Oncology, OncoTargets and Therapy and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact